Vascular endothelial growth factor (VEGF) and ovarian carcinoma cell supernatant activate signal transducers and activators of transcription (STATs) via VEGF receptor-2 (KDR) in human hemopoietic progenitor cells

Gynecologic Oncology

Volumn 94, Issue 1, 2004, Pages 125-133

  Ye, Feng ^a   Chen, Huai Zeng ^a   Xie, Xing ^a   Ye, Da Feng ^a   Lu, Wei Guo ^a   Ding, Zhi Ming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD34+ hemopoietic progenitor cells; Ovarian neoplasms; Signal transducers and activators of transcription; Vascular endothelial growth factor; Vascular endothelial growth factor receptor 2

Indexed keywords

ALANYLTHREONYLTRYPTOPHYLLEUCYLPROLYLPROLYLARGININE; CD34 ANTIGEN; HEPTAPEPTIDE; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CULTURE; CELL ISOLATION; CELL NUCLEUS; CELL SECRETION; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SUPERNATANT; UMBILICAL CORD BLOOD; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIGENS, CD34; CELL COMMUNICATION; CELL NUCLEUS; CULTURE MEDIA; DNA-BINDING PROTEINS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MILK PROTEINS; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 3242733235     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.038     Document Type: Article

References (40)

1. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309
2. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res. 67:1995;281-316
3. Zeng G., Gao L., Birkle S., et al. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res. 60:2000;6670-6676
4. Zhu Z., Hattori K., Zhang H., et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia. 17:2003;604-611
5. Millauer B., Longhi M.P., Plate K.H., et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1996;1615-1620
6. Smith S.L., Agbemadzo B., Reems J.A., et al. Expansion of CD34+KDR+ cells in cord blood after culture with TPO, FLT-3L, SCF, and VEGF. Exp. Hematol. 28:2000;94
7. Rafii S., Meeus S., Dias S., et al. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin. Cell Dev. Biol. 13:2002;61-67
8. Banich J.C., Kolesiak K., Young M.R. Chemoattraction of CD34+ progenitor cells and dendritic cells to the site of tumor excision as the first step of an immunotherapeutic approach to target residual tumor cells. J. Immunother. 26:2003;31-40
9. Gabrilovich D., Ishida T., Oyama T., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 92:1998;4150-4166
10. Nakayama N., Fang I., Elliott G. Natural killer and B-lymphoid potential in CD34+ cells derived from embryonic stem cells differentiated in the presence of vascular endothelial growth factor. Blood. 91:1998;2283-2295
11. Oyama T., Ran S., Ishida T., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160:1998;1224-1232
12. Nakul-Aquaronne D., Bayle J., Frelin C. Coexpression of endothelial markers and CD14 by cytokine mobilized CD34+ cells under angiogenic stimulation. Cardiovasc. Res. 57:2003;816-823
13. Fernandez P.B., Lucibello F.C., Zuzarte M., et al. Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur. J. Cell Biol. 80:2001;99-110
14. Iwamoto M., Shinohara H., Miyamoto A., et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer. 104:2003;92-97
15. Lissoni P., Malugani F., Bonfanti A., et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J. Biol. Regul. Homeost. Agents. 15:2001;140-144
16. Ziegler B.L., Valtieri M., Porada G.A., et al. KDR receptor: a key marker defining hematopoietic stem cells. Science. 285:1999;1553-1558
17. Katoh O., Tauchi H., Kawaishi K., et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55:1995;5687-5692
18. Waltenberger J., Claesson-Welsh L., Siegbahn A., et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:1994;26988-26995
19. David M., Chen H.E., Goelz S., et al. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15:1995;7050-7058
20. Decker T., Meinke A. Jaks, Stats and the immune system. Immunobiology. 198:1997;99-111
21. Kirito K., Watanabe T., Sawada K., et al. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J. Biol. Chem. 277:2002;8329-8337
22. Boland M.P. DNA damage signalling and NF-kappaB: implications for survival and death in mammalian cells. Biochem. Soc. Trans. 29:2001;674-678
23. Fung M.M., Rohwer F., McGuire K.L. IL-2 activation of a PI3 K-dependent STAT3 serine phosphorylation pathway in primary human T cells. Cell. Signal. 15:2003;625-636
24. Jenkins B.J., Quilici C., Roberts A.W., et al. Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. Exp. Hematol. 30:2002;1248-1256
25. Majka M., Ratajczak J., Villaire G., et al. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets. Exp. Hematol. 30:2002;751-760
26. Bhattacharya S., Schindler C. Regulation of Stat3 nuclear export. J. Clin. Invest. 111:2003;553-559
27. Mascareno E., Dhar M., Siddiqui M.A. Signal transduction and activator of transcription (STAT) protein-dependent activation of angiotensinogen promoter: a cellular signal for hypertrophy in cardiac muscle. Proc. Natl. Acad. Sci. U. S. A. 95:1998;5590-5594
28. Bartoli M., Gu X., Tsai N.T., et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J. Biol. Chem. 275:2000;33189-33192
29. Niculescu F., Soane L., Badea T., et al. Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5 b-9 complement complex in aortic endothelial cells. Immunopharmacology. 42:1999;187-193
30. Sato K., Nagayama H., Takahashi T.A. Generation of dendritic cells from fresh and frozen cord blood CD34+ cells. Cryobiology. 37:1998;362-371
31. Binetruy-Tournaire R., Demangel C., Malavaud B., et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 19:2000;1525-1533
32. Nagy J.A., Meyers M.S., Masse E.M., et al. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res. 55:1995;369-375
33. Waltenberger J., Claesson-Welsh L., Siegbahn A., et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:1994;26988-26995
34. Zandstra P.W., Lauffenburger D.A., Eaves C.J. A ligand-receptor signaling threshold model of stem cell differentiation control: a biologically conserved mechanism applicable to hematopoiesis. Blood. 96:2000;1215-1222
35. Berthier-Vergnes O., Gaucherand M., Peguet-Navarro J., et al. Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells. Br. J. Cancer. 85:2001;1944-1951
36. Bautz F., Rafii S., Kanz L., et al. Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment. Exp. Hematol. 28:2000;700-706
37. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23:2001;263-272
38. Santin A.D., Hermonat P.L., Ravaggi A., et al. Secretion of vascular endothelial growth factor in ovarian cancer. Eur. J. Gynaecol. Oncol. 20:1999;177-181
39. Wiederkehr-Adam M., Ernst P., Muller K., et al. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J. Biol. Chem. 278:2003;16117-16128
40. Yu Z., Zhang W., Kone B.C. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem. J. 367:2002;97-105